Three analyses of the LITESPARK trial examining the hypoxia-inducible factor 2a (HIF-2a) belzutifan (Welireg) showed efficacy and benefit for this novel therapy over comparator treatments in advanced clear cell renal cell carcinoma (RCC) as well … Continue reading Belzutifan results “practice changing” at ESMO 2023